Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Results from GLP preclinical study of AAV8-hCocH gene therapy

Jan. 22, 2020

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 8, 2020

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Jan. 3, 2020

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Dec. 24, 2019

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

Dec. 20, 2019

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...